SEC Form 4 · accession 0001209191-15-077365
INSITE VISION INC · INSV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy M Ruane
Officer — Chief Executive Officer · Director
Period of report
Oct 28, 2015
Accepted (ET)
Oct 30, 2015 · 11:30 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000802724
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 28, 2015 | U | 200,000 | $0.35 | D | 0 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On October 28, 2015, Thea Acquisition Corp, ("Purchaser"), a wholly owned subsidiary of Ranbaxy, Inc. ("Ranbaxy"), which is an indirect wholly owned subsidiary of Sun Pharmaceutical Industries Ltd., completed a tender offer for all the outstanding shares of InSite Vision Incorporated ("Issuer") for a purchase price of $0.35 per share, all pursuant to that certain Agreement and Plan of Merger, dated September 15, 2015, as amended and restated, by and among Purchaser, Ranbaxy and Issuer.